NCAM-1
NCAM-1 Molekülinformation
| Englischer Name | Neural cell adhesion molecule 1 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 6 | Target-Alias | Neural cell adhesion molecule 1，CD56，NCAM1，NCAM，Neural Cell Adhesion Molecule， NCAM，CD56 Antigen，N-CAM-1，MSK39，NCAM-1，Antigen Recognized By Monoclonal Antibody 5.1H11 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical | ||
| Englischer Name | Neural cell adhesion molecule 1 |
| Target-Alias | Neural cell adhesion molecule 1，CD56，NCAM1，NCAM，Neural Cell Adhesion Molecule， NCAM，CD56 Antigen，N-CAM-1，MSK39，NCAM-1，Antigen Recognized By Monoclonal Antibody 5.1H11 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 6 |
| Höchste Forschungs- und Entwicklungsphase | Phase 2 Clinical |
NCAM-1 Produktliste
- Attribut
Protein (9)
- Produktbibliothek
Online (9)
- Spezies
Human (8)Mouse (1)
- Etikett
His Tag (5)Fc Tag (2)His Tag & Avi Tag (1)Llama IgG Fc Tag (1)
- Marker
Unconjugated (4)Biotin-labeled (1)FITC Labeled (2)AF488 Labeled (1)AF647 Labeled (1)
In den Warenkorb legen
Gesamtmenge9
- 1
NCAM-1 Molekülhintergrund
NCAM1 belongs to the immunoglobulin superfamily of adhesion molecules. A wide range of alternatively spliced NCAM1 messenger RNAs (mRNAs) has been described to date, but only the 120-, 140-, and 180- kDa isoforms are commonly expressed. NCAM1 plays an important role in the regulation of neurogenesis, neurite outgrowth, proliferation, and cell migration, however, its function in hematopoiesis, including NK cells, is poorly understood. NCAM1 signaling is mediated either by homophilic or heterophilic interactions with fibroblast growth factor receptor (FGFR), L1-CAM, N-cadherin and other components of the extracellular matrix. Upon activation, NCAM1 triggers a variety of signaling cascades including FYN–focal adhesion kinase (FAK), MAPK, and phosphatidylinositol 3-kinase (PI3K) pathways.
NCAM-1 Molekülalias
CD56,MSK39,NCAM1,N-CAM-1
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Carcinoma, Merkel Cell; Leukemia; Multiple Myeloma; Neuroblastoma; Neurofibrosarcoma; Ovarian Neoplasms; Pulmonary Blastoma; Rhabdomyosarcoma; Sarcoma, Synovial; Small Cell Lung Carcinoma; Wilms Tumor | Details |
| EB-DART-NK01 | EB-DART-NK01 | Phase 2 Clinical | Beijing Biotech | Small Cell Lung Carcinoma | Details |
| CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
| GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
| DXC-006 | DXC-006; DAC-006 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Hematologic Neoplasms; Lung Neoplasms; Solid tumours | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation